Tarsus Pharmaceuticals Adds Industry Veteran to Board

Tarsus Pharmaceuticals ( (TARS) ) has issued an update.

On February 18, 2026, Tarsus Pharmaceuticals expanded its board from seven to eight members and appointed veteran biopharmaceutical executive David E. I. Pyott, former chairman and CEO of Allergan, as a Class III director, effective immediately. Pyott was simultaneously named chair of the Board’s Commercial Committee and a member of its Nominating and Compensation Committees, with the Board deeming him independent under Nasdaq and SEC standards.

Pyott, known for transforming Allergan from a $1 billion eye-care company into a $7 billion global specialty pharmaceutical and medical device leader, joins Tarsus as it scales XDEMVY and advances a pipeline in eye care and related specialties. His appointment, supported by a standard non-employee director cash and equity package and an indemnification agreement in line with other Tarsus directors, signals a bid to bolster commercial execution and long-term growth strategy at a pivotal phase for the company.

The most recent analyst rating on (TARS) stock is a Hold with a $68.00 price target. To see the full list of analyst forecasts on Tarsus Pharmaceuticals stock, see the TARS Stock Forecast page.

Spark’s Take on TARS Stock

According to Spark, TipRanks’ AI Analyst, TARS is a Neutral.

Tarsus Pharmaceuticals’ overall stock score reflects a strong technical performance and positive earnings call sentiment, offset by financial challenges. The company’s robust revenue growth and successful product launch are significant strengths, but profitability and cash flow issues weigh on the score. The technical indicators suggest bullish momentum, although caution is advised due to overbought signals. Valuation remains a concern with negative earnings impacting the P/E ratio.

To see Spark’s full report on TARS stock, click here.

More about Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company focused on applying proven science and new technology to revolutionize treatment for patients, beginning with eye care. The company markets XDEMVY, an FDA-approved therapy for Demodex blepharitis in the U.S., and is advancing a pipeline including TP-04 for ocular rosacea and TP-05 for prevention of Lyme disease, both in Phase 2 development.

Tarsus targets diseases with high unmet need across eye care, dermatology and infectious disease prevention, aiming to build a diversified portfolio of specialty treatments. Its strategy centers on scaling its lead commercial eye-care product while progressing a broader pipeline to strengthen its position in key specialty markets.

Average Trading Volume: 565,023

Technical Sentiment Signal: Buy

Current Market Cap: $2.58B

For an in-depth examination of TARS stock, go to TipRanks’ Overview page.